Date: 2011-03-31
Type of information: Fundraising
Company: Acacia Pharma (UK)
Investors: Lundbeckfond Ventures (Denmark) - Gilde Healthcare (The Netherlands)
Amount: $10 million (€7 million)
Funding type: Series A financing round
Planned used: Acacia Pharma will use the proceeds to complete Phase II development of its two lead product opportunities, APD421 for the prevention of nausea & vomiting in post-surgical patients and APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.
Others: Acacia Pharma has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series A financing. As a consequence of the investment, Associate Professor Johan Kördel of Lundbeckfond Ventures will join the Board of Acacia Pharma.
Therapeutic area: Cancer - Oncology
